mild transthyretin familial amyloid polyneuropathy (TTR-FAP) - Articles and news items

Pfizer’s Vyndaqel a success for rare disease

Industry news / 8 August 2016 / Pfizer

Treatement over varying periods of up to 5.5 years, showed that early stage treatment with Vyndaqel resulted in minimal neurological disease progression, and in preservation of body weight, which often declines as the disease progresses…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+